- Sanofi shows its continued commitment to patients’ needs in emerging markets and improves access to innovative, affordable devices –
Paris, France – October 9, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the launch by Sanofi India Limited of AllStar™, the first Indian-manufactured, re-usable insulin pen, manufactured by a global company in India. Developed especially for patients in emerging markets, AllStar™ is indicated for use of insulinized patients using Sanofi’s insulin portfolio, and also for insulin-naive patients who are starting to use insulin. The AllStar™ re-usable insulin pen conforms to ISO (International Organization for Standardization) standards and is equipped with state-of-theart features.
AllStar™ will be commercially launched in India this October. The launch of AllStar™ is a significant milestone emblematic of Sanofi’s leadership in addressing the needs of people with diabetes in India. It highlights Sanofi’s commitment to diabetes and emerging markets and its regionalized approach to finding solutions that are adapted to local market needs. Going forward, Sanofi intends to make AllStar™ accessible to other emerging markets.
“Sanofi has always been at the forefront of diabetes research and development. AllStar™ is a testament to Sanofi’s patient-centric approach and leverages our strong commitment to embracing innovation coming from emerging markets like India,” says Pierre Chancel, Senior Vice President,Global Diabetes, Sanofi. “Sanofi India’s manufacturing its own re-usable insulin device is the results of three years of exemplary team work with the sole purpose of offering a device that would match the needs of people with diabetes in India and other emerging markets.”
AllStar™ is a state-of-the-art device that is easy-to-use for patients, and also supports physicians in early initiation of insulin therapy for better glycemic control and enhanced therapeutic outcomes.
AllStar™ is the result of a successful collaborative multidisciplinary, cross-functional and multicountry effort lead by Industrial Development within Sanofi that brought together technology, resources and intellectual capital to develop a pen that patients aspire for; one that combines convenience and affordability. AllStar™ is a combination of sleek design styling with easy-to-use, yet sophisticated technology.
With close to 63 million people with diabetes in India, of whom many are either undiagnosed or have uncontrolled diabetes because of poor compliance, diabetes is a major health problem in India. Given the social and economic impact of diabetes, Sanofi finds it critical to invest in local talent to bring innovative devices to local patients.
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative,integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics,therapies, services and devices, including innovative blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.Investigational compounds in the pipeline include an injectable GLP-1 receptor agonist being studied as a single agent, in combination with basal insulin, and/or in combination with oral antidiabetic agents.
For more information:
Last updated on: 10/10/2012